Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Find My GLP-1 Path

Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

Does Insurance Cover Zepbound for Sleep Apnea? 2026 Guide

By The RX Index Editorial Team ·

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This guide is educational and is not medical, legal, or insurance advice. We may earn a commission if you use some provider links below. That never changes the coverage rules, prices, or source documents we show you.

Does insurance cover Zepbound for sleep apnea? Often, yes — but almost never automatically.

Some commercial plans and Medicare Part D plans can cover Zepbound (tirzepatide) when it's prescribed for the condition the FDA approved it for: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The catch lives in the fine print. Your plan has to list it, you'll need a sleep study and a prior authorization, and the request has to be filed as sleep apnea treatment — not weight loss.

Quick answer by your situation

Your situationIs coverage possible?Your first move
Commercial/employer plan + OSA diagnosis + BMI 30+Often yes — depends on your planCheck your drug list, file an OSA-specific prior auth
Federal employee (FEHB) planOften yes, plan-dependentRun a free coverage check, then file the PA
Medicare Part D, prescribed for OSAYes — through regular Part D (not the new $50 Bridge)Ask your plan if it's covered for OSA
Denied as a “weight-loss drug”Often fixable — unless it's a hard plan exclusionMatch the denial reason to the missing document
No sleep study yetNot ready for a prior authAsk your doctor about a sleep study
Plan excludes obesity meds entirelyMaybe — depends if the exclusion also blocks the OSA pathAsk for the written exclusion; if there's no exception, compare self-pay

Have commercial or federal-employee (FEHB) insurance?

The fastest way to stop guessing is a free coverage check. Ro's free GLP-1 Insurance Coverage Checker uses your insurance info to contact your insurer and send back a personalized coverage report — including whether prior authorization is required. If you later join Ro and a Ro-affiliated provider approves treatment, Ro says its insurance team gets the coverage process started for you.

Check your Zepbound coverage free with Ro → (sponsored affiliate link, opens in a new tab)

On Medicare or Medicaid? Skip to the Medicare section — Ro can't coordinate government coverage (except FEHB), and you have a different, better path.

Does insurance cover Zepbound for sleep apnea?

Answer: Yes, some plans do — but only when the request clears your plan's drug list, diagnosis, documentation, and prior-authorization rules. The cleanest path is documented moderate-to-severe obstructive sleep apnea in an adult with obesity, filed under the sleep apnea (OSA) indication, with a sleep study and BMI on record. Coverage is never guaranteed, and it almost always needs prior authorization. (Source: FDA; payer policies.)

Think of coverage as four gates, all of which have to line up:

Your plan lists the drug. If Zepbound isn't on your formulary (your plan's list of covered drugs), you'll need a formulary exception.

Your diagnosis qualifies. Moderate-to-severe OSA, in an adult with obesity.

Your documents prove it. A sleep study and a current BMI are the big two.

The request is filed for sleep apnea. Not "weight loss" -- this is where most people quietly lose.

Coverage is most likely when you have a sleep study showing moderate-to-severe OSA, a BMI of 30 or higher, and a doctor's office that submits the prior authorization under the sleep apnea indication with the right chart notes. Coverage is least likely when the prescription goes in as weight loss only, there's no sleep study attached, the OSA is mild rather than moderate-to-severe, or the plan has a hard exclusion with no medical exception.

Is Zepbound really FDA-approved for sleep apnea — and does it work?

Answer: Yes. On , the FDA approved Zepbound as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. That approval matters for your wallet, not just your health — it gave Zepbound a real medical reason to be covered, separate from weight loss. (Source: FDA; Eli Lilly.)

The trial that earned the approval, SURMOUNT-OSA, ran two 52-week studies in adults with moderate-to-severe OSA and a BMI of 30 or higher. Here's what it found, straight from Eli Lilly's clinical data:

SURMOUNT-OSA result (52 weeks)Study 1 — not using CPAPStudy 2 — using CPAP
Drop in AHI (breathing events/hour) on Zepbound25.3 fewer events/hour29.3 fewer events/hour
Drop in AHI on placebo5.3 fewer events/hour5.5 fewer events/hour
Percent reduction in AHI on Zepbound50.7%58.7%
Reached remission or mild, non-symptomatic OSA42.2% (vs 15.9% on placebo)50.2% (vs 14.3% on placebo)
Source: Eli Lilly; results published in the New England Journal of Medicine.

In plain terms: the AHI is the number of times your breathing stops or gets shallow each hour of sleep — it's how doctors grade sleep apnea. People on Zepbound cut that number by about half, and roughly four to five out of ten reached remission or mild OSA, versus about one and a half out of ten on placebo.

A few honest notes: those are study averages, and your own results may differ. Zepbound is approved as an add-on to a reduced-calorie diet and more activity — not a standalone fix. And it's approved for OSA tied to obesity: it works by helping you lose weight, which eases the load on your airway, and the FDA notes the breathing improvement is likely related to that weight loss. The two numbers that show up in your insurance rules: moderate-to-severe OSA (AHI of 15 or more) and obesity (BMI of 30 or more). Hold onto those two — they're the gatekeepers for everything that follows.

Will commercial insurance cover Zepbound for sleep apnea?

Answer: Sometimes — and your sleep apnea diagnosis is often the key that unlocks it. Coverage is genuinely mixed across commercial plans, and almost every one requires prior authorization. But here's the move most people miss: a number of plans that flat-out exclude weight-loss drugs will still cover Zepbound under the obstructive sleep apnea indication, because OSA is a documented medical condition — not “cosmetic” weight loss. (Source: payer policies from UnitedHealthcare, CVS Caremark, Aetna.)

UnitedHealthcare publishes a specific “Zepbound — Obstructive Sleep Apnea Only” prior-authorization policy that allows coverage of Zepbound for obesity with OSA even on plans where weight-loss drugs otherwise aren't covered. CVS Caremark and Aetna have their own OSA criteria built around the same core proof. The lesson is simple: the words on your prior authorization matter as much as your diagnosis.

The denial trap: “weight loss” vs. “sleep apnea”

This is the single most common way people lose.

Your doctor prescribes Zepbound, the request gets processed as a weight-loss medication, your plan excludes weight-loss meds, and you get an automatic “no” — even though you have a real, documented sleep apnea diagnosis your plan might actually cover. The fix isn't to give up. It's to make sure the request is submitted under the OSA indication, with the sleep study attached.

One honest note: if your specific employer plan has a hard exclusion on all anti-obesity medications with no medical-necessity exception, an appeal may go nowhere, no matter how clean your paperwork is. That's a real wall. But if your denial happened because the request was treated as “weight loss” instead of documented moderate-to-severe sleep apnea, that's not a wall — it's a fixable filing error, and the OSA path is your way through.

The CVS Caremark story (the part that's changing right now)

If you have a CVS Caremark plan, your coverage has been a moving target. Here's the current timeline:

  • July 1, 2025: CVS Caremark removed Zepbound from its major commercial drug lists and made Wegovy its preferred GLP-1. The change affected an estimated 200,000 patients and prompted a class-action lawsuit.
  • Effective June 1, 2026: CVS Caremark is lifting its “new-to-market” block on Foundayo (Eli Lilly's GLP-1 pill) where plans choose to cover it.
  • Effective October 1, 2026: CVS Caremark is adding Zepbound back to its commercial drug lists as an additional preferred option. Plan sponsors still decide whether to cover GLP-1s at all.

(Source: Reuters; Managed Healthcare Executive; CVS Health.) Two takeaways. First, even while Zepbound sat off the weight-loss list, the sleep apnea indication gave many patients a stronger case for a formulary exception — because Wegovy, the preferred alternative, isn't FDA-approved for OSA, so there was no equal substitute to point them to. Second, check your plan's current status before you assume anything.

If your plan covers GLP-1s but you're facing prior authorization, step therapy, or a denial, you don't have to fight the paperwork alone. For commercial and FEHB members, Ro runs a dedicated insurance team that contacts your insurer and, once you're a member and approved for treatment, submits the prior authorization for you.

See if you're covered and let Ro handle the prior authorization → (sponsored affiliate link, opens in a new tab)

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Membership is $39 first month, then $149/month or as low as $74/month annually. Medication cost is separate.

What do major payer policies actually require?

Answer: There's no single national checklist — but the big plans line up on the essentials: a sleep study showing moderate-to-severe OSA (AHI of at least 15), obesity (BMI of at least 30), and proof of diet-and-exercise effort, filed under the sleep apnea indication. Below is what we found in the published criteria for three of the largest commercial payers. Always confirm your own plan. (Source: UnitedHealthcare, CVS Caremark, Aetna.)
Plan / PBMOSA-specific coverage path?BMI ruleSleep-study ruleDiet/activity ruleInitial approvalTo renew
UnitedHealthcareYes — a dedicated “Zepbound — OSA Only” policy that can cover OSA even if weight-loss drugs are excludedBMI ≥30Moderate-to-severe OSA on a sleep study; AHI/REI/RDI ≥15Reduced-calorie diet and activity, plus at least one prior weight-loss attempt on record~6 monthsShow response (improved sleep measures and/or weight)
CVS CaremarkYes — OSA criteria (Zepbound returns to commercial lists Oct 1, 2026)BMI ≥30Moderate-to-severe OSA on PSG or home sleep test; AHI ≥15Reduced-calorie diet and increased physical activity documented~6 months~12 months; requires a positive response / fewer OSA symptoms
AetnaYes — OSA criteriaBMI ≥30Moderate-to-severe OSA on PSG or home sleep test; AHI ≥15Reduced-calorie diet and increased physical activity documentedPer policyPositive response plus maintenance dosing
The pattern: AHI 15 is the severity gate, BMI 30 is the obesity gate, and your sleep study is the document that opens both. Notice what's not required on the OSA path that often is on the weight-loss path — there's no BMI-27-plus-comorbidity shortcut here; the sleep apnea criteria use BMI 30. And the long “6-month structured weight program” you may have read about usually belongs to weight-management criteria, not the OSA-specific path.

What documents do insurers want for a prior authorization?

Answer: Across the major plans, the pattern is the same: objective proof, not a good story. You need a sleep study showing moderate-to-severe OSA, proof of obesity, and the request filed for sleep apnea — plus a few extras some plans add. Get those right and you clear the part that trips most people up. (Source: UnitedHealthcare, CVS Caremark, and Aetna policies; FDA label.)

Your prior authorization checklist

  • A sleep study reporteither an in-lab polysomnography (PSG) or a home sleep apnea test
  • An AHI (or REI/RDI) of at least 15 events per hourthe line between mild and moderate OSA
  • A diagnosis of moderate-to-severe OSAin your chart
  • Current height, weight, and BMIfor the OSA path, plans like UnitedHealthcare, CVS Caremark, and Aetna use BMI 30 or higher
  • The prescription filed for the OSA indicationthe step that prevents the "weight loss" denial
  • ICD-10 codes on the claimG47.33 (obstructive sleep apnea) plus an obesity code such as E66.x
  • Documented diet and activity efforta reduced-calorie diet and more activity; UnitedHealthcare also wants at least one past weight-loss attempt on record
  • CPAP/PAP notes if your plan asksadherence, intolerance, or why you're not a candidate
  • A letter of medical necessityfrom your prescriber for borderline cases or appeals
Two numbers do most of the heavy lifting. AHI 15 is the severity gate. BMI 30 is the obesity gate. If your sleep study and your chart clearly show both, you've handled the hardest part. Incomplete documentation is one of the most common denial reasons — and the most preventable.

Hand this to your doctor

You don't have to be the expert. You just have to ask the right question. Copy this and bring it to your appointment:

“My plan may cover Zepbound when it's prescribed for FDA-approved moderate-to-severe obstructive sleep apnea in an adult with obesity. Can your office submit the prior authorization under the OSA indication and include my sleep study, my AHI, my BMI, my chart notes, and my CPAP history if the plan requires it?”

One thing we won't tell you to do: ask anyone to put down a diagnosis that isn't accurate. You don't need to. If you genuinely have moderate-to-severe OSA and obesity, the request just needs to reflect the condition you're actually being treated for.

Does Medicare cover Zepbound for sleep apnea?

Answer: Yes — Medicare Part D can cover Zepbound for moderate-to-severe sleep apnea in adults with obesity, even though Medicare won't cover it for weight loss alone. You'll need a Part D plan, both diagnoses (OSA and obesity), a sleep study, and prior authorization. And there's one trap to dodge that catches almost everyone. (Source: CMS; Medicare plan policies.)

The trap: the Medicare GLP-1 Bridge is NOT the path for sleep apnea

You may have heard about the Medicare GLP-1 Bridge — a program offering Zepbound and Wegovy for a $50 monthly copay, starting and running through . It's real. But the Bridge is for weight loss, not sleep apnea. CMS is clear that when Zepbound is prescribed for OSA, it goes through your regular Part D plan— your normal drug list, prior authorization, and cost-sharing — not the $50 Bridge. (Source: CMS Medicare GLP-1 Bridge guidance.)

If Zepbound is prescribed for…Your Medicare route
Moderate-to-severe OSA with obesityRegular Part D — formulary + prior auth (not the Bridge)
Weight loss / obesity onlyThe Medicare GLP-1 Bridge, if you meet the program's criteria ($50/mo)
You're not sure whyAsk your prescriber which diagnosis is on the prescription

On regular Part D, you pay your plan's cost-sharing, but your out-of-pocket on covered Part D drugs is capped at $2,100 for 2026 — though that ceiling only helps if your plan actually covers the drug or approves it through an exception. And manufacturer savings cards don't work with Medicare, Medicaid, TRICARE, or VA coverage — that's federal law. For Medicare, call the number on your plan card and ask: “Is Zepbound on my formulary for obstructive sleep apnea, and what's the prior authorization?” For the full Medicare picture, see our Does Medicare Cover Zepbound guide.

What about Medicaid?

Medicaid is state-by-state. Coverage of GLP-1s for obesity is limited — only a handful of states cover them. But the sleep apnea indication can be treated differently, because Medicaid programs generally cover FDA-approved drugs for their approved uses, subject to the state's rules. So a “no” for weight loss isn't automatically a “no” for OSA. Check your state's Medicaid formulary and prior-authorization rules before assuming either way. (Source: KFF.)

Not sure whether you're in the regular Part D lane, the Bridge lane, or a state Medicaid path? Our free 60-second matching quiz sorts you into the right one.

Get your personalized GLP-1 action plan →

How much does Zepbound cost for sleep apnea — with and without insurance?

Answer: With eligible commercial coverage and the manufacturer savings card, most people pay about $25 a month. Without coverage, self-pay through LillyDirect (sponsored affiliate link, opens in a new tab) runs $299–$449 a month — far below the roughly $1,086 retail price. Your exact cost depends on your plan, your deductible, and which path you land on. (Source: Eli Lilly pricing pages.)
Your pathWhat you'll likely pay per monthThe fine print
Commercial plan covers it + savings card~$25/monthEligibility limits apply; savings card not for government insurance
Commercial plan doesn't cover it + savings card~$499/monthA pen-based discount; verify current terms at zepbound.lilly.com
Self-pay through LillyDirect (sponsored affiliate link, opens in a new tab) (no insurance)$299–$449/month$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg). For 7.5–15 mg, the $449 price requires the 45-day refill timing; miss it and regular prices apply.
Medicare Part D (covered for OSA)Your plan's cost-sharingCapped at $2,100 total out-of-pocket in 2026. Savings card not allowed.
Single-dose pen / retailUp to ~$1,086/fillHardly anyone pays this — check the savings, insurance, LillyDirect, and exception paths above first.

The $1,086 list price is rarely what anyone actually pays — there's almost always a cheaper path. And Medicare and Medicaid patients can use LillyDirect self-pay — you just can't run it through your government plan or use a savings card, and Lilly's cash terms ask that you not seek reimbursement.

If you'd rather get help through a telehealth provider, Ro carries FDA-approved Zepbound. Ro's membership is $39 for the first month, then $149/month — or as low as $74/month on an annual plan paid upfront. Important: that membership covers visits and insurance support; the medication cost is separate (your copay if covered, or the cash/savings price if not).

If insurance might work, a free coverage check is the cheapest first move. If it won't, don't assume retail is your only option.

Check your Zepbound coverage and cash-pay options with Ro → (sponsored affiliate link, opens in a new tab)

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

What if you're denied — or your plan calls it “weight loss”?

Answer: A denial is rarely the final word. The trick is reading why you were denied, then sending back exactly what that reason demands. Most denials aren't “you don't qualify” — they're “your paperwork didn't match our rules.” And Zepbound has a strong appeal argument, because among GLP-1 medications it's the only one FDA-approved for sleep apnea. (Source: payer policies; FDA.)

Find your denial language on the left and do what's on the right:

What the denial saysWhat it usually meansYour best next move
"Weight-loss medications are excluded"Filed as weight loss, not OSAAsk if there's a separate OSA prior-auth or exception path
"Not medically necessary"Missing clinical proofResubmit with sleep study, AHI, BMI, and a medical-necessity letter
"Prior authorization required"Not a denial yetHave your prescriber submit the full PA packet
"Not on formulary"Drug isn't on your listRequest a formulary exception tied to the OSA diagnosis
"Step therapy required"Plan wants another drug tried firstAsk what's required, and whether your OSA diagnosis qualifies for an exception
"Missing information"A document gapSend the sleep study, BMI, diagnosis, and CPAP notes
"Plan exclusion"A harder wallConfirm whether the exclusion covers the OSA indication or only weight loss

What to attach to an appeal:

Your denial letter, your sleep study, BMI documentation, your prescriber's letter of medical necessity, your OSA diagnosis and severity, CPAP notes if relevant, and any formulary-exception form your plan uses.

Your first appeal doesn't need to be an aggressive legal letter. Clean and factual wins:

“This request is for FDA-approved treatment of moderate-to-severe obstructive sleep apnea in an adult with obesity — not weight loss alone. Attached are the sleep study results, BMI documentation, diagnosis notes, and prescriber rationale required under the plan's prior authorization criteria. Among GLP-1 medications, Zepbound is the only one FDA-approved for this condition.”
That last line is your leverage. Among GLP-1s, there's no equal drug your plan can steer you to instead — because no other one carries the sleep apnea approval.

What if your employer or pharmacy plan excludes GLP-1s?

Answer: Employer plans can block coverage even when a drug is FDA-approved — but the exclusion isn't always as total as it looks. The key question is what the exclusion covers: weight-loss use only, all anti-obesity meds, all GLP-1s, or Zepbound for every reason. The answer changes your options.
A piece almost nobody explains: your pharmacy manager's name on your card — CVS Caremark, Express Scripts, OptumRx — doesn't tell you your coverage. Employers customize their own benefits. Two people with the same pharmacy manager can have completely different Zepbound coverage because their employers chose different drug lists. So the only reliable answer comes from your specific plan.

Call your HR or benefits team and ask, in this order:

  1. “Is Zepbound covered under our pharmacy benefit?”
  2. “Is there a separate coverage path for FDA-approved sleep apnea?”
  3. “Is the exclusion for weight-loss medications only, or for all uses of Zepbound?”
  4. “Is prior authorization or a formulary exception available?”
  5. “Can you send me the written policy or the basis for any denial?”

If the answer is a true, no-exceptions exclusion, don't burn weeks on a losing appeal. Move to self-pay (LillyDirect at about $299–$449/month), or take our quiz to map the cheapest path for your situation. The right person for an appeal is someone with a coverable diagnosis and a fixable filing problem — not someone fighting a brick wall.

Is Zepbound a replacement for CPAP?

Answer: No — not automatically, and not on your own. Zepbound is an approved treatment option for moderate-to-severe OSA in adults with obesity, but whether it replaces, adds to, or sits alongside your CPAP is a decision for your sleep doctor. (Source: FDA label.)

CPAP is still a frontline OSA treatment, and many people benefit from it. In the trials, tirzepatide helped people both with and without a CPAP machine. Some people may end up using both for a while. Do not stop CPAP or change your sleep apnea treatment without your clinician's direction — and there's an insurance reason to keep good CPAP records, too: some plans ask about your CPAP use (or why you can't tolerate it) as part of approving Zepbound.

What we won't say, because none of it is true or safe: that Zepbound “replaces CPAP,” that every OSA patient qualifies, or that your apnea is guaranteed to resolve.

What people keep running into

One pattern shows up over and over: people who clearly meet the criteria, with a sleep study in hand, still get denied — because the request was processed as “weight loss” rather than sleep apnea. The frustration is real, and it's usually fixable with the right refiling under the OSA indication.

For a sense of scale on coverage itself, here's a real data point worth keeping in perspective: Ro's 2025 GLP-1 Insurance Coverage Checker report found that 43% of users had coverage for a GLP-1 (for weight loss), and half of those covered paid $50 a month or less. (Source: Ro.) Don't read that as “43% of plans cover Zepbound for sleep apnea” — your OSA result still depends on your plan, your formulary, your diagnosis, and your prior authorization. But it does say what the horror stories don't: coverage is more common than you'd think. You just have to find out where you stand.

Quick reminder: insurance approval is about coverage, not about whether Zepbound is right for your body — only a licensed clinician can decide that. Zepbound carries a boxed warning about thyroid C-cell tumors and is not for people with a personal or family history of medullary thyroid cancer or MEN 2. The FDA also lists warnings for severe stomach and intestinal problems, acute pancreatitis, gallbladder problems, low blood sugar (especially with insulin or certain diabetes drugs), acute kidney injury, serious allergic reactions, worsening diabetic eye disease in people with type 2 diabetes, suicidal thoughts or behavior, and a risk of breathing in stomach contents during surgery or deep sedation.

And to be crystal clear — compounded tirzepatide is not Zepbound, it isn't FDA-approved, and it is not the subject of this insurance guide. (Source: FDA label.)

What we actually verified

We separate three kinds of facts: official medical and regulatory facts (the FDA approval, CMS Medicare rules, published trial results), verified commercial facts (current prices and policies, checked against payer and manufacturer sources), and our editorial judgment (clearly labeled as opinion).

ClaimStatusWho it applies to
Zepbound is FDA-approved for moderate-to-severe OSA in adults with obesity (Dec 20, 2024)Verified (FDA)Everyone
Some plans cover the OSA indication even when they exclude weight-loss drugsVerified (UnitedHealthcare and others)Commercial plans with an OSA path
Every plan must cover Zepbound for OSAFalse -- coverage is plan-specific--
The Medicare $50 GLP-1 Bridge is the path for sleep apneaFalse -- OSA goes through regular Part D (CMS)Medicare Part D
Savings card can lower cost to about $25/monthVerified, with eligibility limits (Eli Lilly)Eligible commercial coverage only
Medicare/Medicaid patients can use the savings cardFalse -- government insurance is excluded--
LillyDirect self-pay: $299 / $399 / $449 by doseVerified, terms apply (Eli Lilly)Cash-pay
CVS Caremark adds Zepbound back to commercial lists Oct 1, 2026Verified (Reuters; Managed Healthcare Executive)CVS Caremark commercial members
Your exact out-of-pocket costDepends on your plan -- verify directlyYou
Our editorial take, stated as opinion: for someone whose core question is “will my insurance cover this,” a free coverage check plus a team that files the prior authorization is the most useful first step — which is why we point commercial and FEHB readers to Ro. For Medicare and most government coverage, the better path is your own plan. That's our recommendation based on the verified facts above, not a guarantee about your plan.

Frequently asked questions

About insurance coverage for Zepbound for sleep apnea.

Does insurance cover Zepbound for sleep apnea?

Some plans do. The strongest path is documented moderate-to-severe obstructive sleep apnea in an adult with obesity, with prior authorization filed under the OSA indication and backed by a sleep study and BMI documentation. Coverage is never automatic and almost always needs prior authorization.

Does Medicare cover Zepbound for sleep apnea?

Medicare Part D can cover Zepbound for OSA through your regular plan's formulary and prior-authorization process. According to CMS, a Zepbound prescription for sleep apnea does not go through the Medicare GLP-1 Bridge -- the Bridge is for weight loss, while OSA is already a Part D-coverable use.

Is the Medicare $50 GLP-1 Bridge the right path for Zepbound sleep apnea?

No. The Bridge ($50/month, July 1, 2026 through December 31, 2027) covers GLP-1s for weight loss. When Zepbound is prescribed for obstructive sleep apnea, it runs through your regular Part D coverage instead.

Does Medicaid cover Zepbound for sleep apnea?

It is state-by-state. Medicaid coverage of GLP-1s for obesity is limited, but because Medicaid generally covers FDA-approved drugs for their approved uses, the sleep apnea indication may be treated differently from weight loss. Check your state's Medicaid formulary and prior-authorization rules before assuming yes or no.

What sleep apnea severity do insurers usually require?

Most OSA criteria require moderate-to-severe sleep apnea documented by a sleep study, commonly an AHI (or REI/RDI) of at least 15 events per hour. Exact wording varies by plan, so check your own policy.

What BMI do I usually need for Zepbound sleep apnea coverage?

For the sleep apnea path, plans like UnitedHealthcare, CVS Caremark, and Aetna use a BMI of 30 or higher. The BMI-27-plus-comorbidity option belongs to the weight-management path, not the OSA-specific one.

Why was I denied as a weight-loss drug if I have sleep apnea?

The request was likely filed as weight loss rather than under the sleep apnea indication, and your plan excludes weight-loss meds. With a documented moderate-to-severe OSA diagnosis, ask your prescriber to refile under the OSA indication, or request a formulary exception or appeal.

Can I use the Zepbound savings card with Medicare?

Generally no. The manufacturer savings card excludes people with government insurance, including Medicare, Medicaid, TRICARE, and VA coverage.

How much does Zepbound cost without coverage?

Self-pay through LillyDirect runs about $299 (2.5 mg), $399 (5 mg), and $449 (7.5-15 mg) per month, versus roughly $1,086 retail for pens. Terms and prices change, so confirm current pricing with Eli Lilly.

Should I stop CPAP if I start Zepbound?

No one should stop CPAP or change sleep apnea treatment without a clinician's direction. Zepbound may be part of an OSA treatment plan for eligible adults with obesity, but that decision belongs with your sleep doctor.

Can I substitute compounded tirzepatide to get around coverage?

No. This page is about insurance coverage for FDA-approved Zepbound. Compounded tirzepatide is not Zepbound, is not FDA-approved, and is not the same coverage path.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz — no sign-up required. It points you to the right lane: commercial prior auth, Medicare Part D, the Bridge, state Medicaid, self-pay, or a provider that handles the paperwork for you.

Get your personalized GLP-1 action plan →

By The RX Index Editorial Team. Prices, drug-list rules, and prior-authorization criteria change often — re-check your plan before you act. This guide is educational and is not medical, legal, or insurance advice.

Sources

  • U.S. Food and Drug Administration — Zepbound approval for obstructive sleep apnea (); Zepbound prescribing information (label).
  • Eli Lilly and Company — SURMOUNT-OSA clinical data; Zepbound pricing, LillyDirect, and savings program terms.
  • New England Journal of Medicine — SURMOUNT-OSA published results.
  • Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge guidance; Part D coverage rules.
  • UnitedHealthcare — “Zepbound (tirzepatide) — Obstructive Sleep Apnea Only” prior-authorization policy.
  • CVS Caremark and Aetna — Zepbound prior-authorization criteria.
  • Reuters; Managed Healthcare Executive; CVS Health — CVS Caremark commercial formulary changes (2025–2026).
  • KFF — Medicaid coverage of GLP-1s.
  • Ro — 2025 GLP-1 Insurance Coverage Checker report; program and coverage-checker terms.

Related guides